ReviewInternational journal of chronic obstructive pulmonary disease2022
The Microbiome in COPD: Emerging Potential for Microbiome-Targeted Interventions.
Review in International journal of chronic obstructive pulmonary disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Global research status and development trends of chronic obstructive pulmonary disease and gut microbiota: a comprehensive analysis based on bibliometrics and knowledge visualization.Frontiers in microbiology · 2026Pooled it
- Review
- Comparative analysis of the sputum microbiota in different COPD clinical states.Scientific reports · 2026Article
- Bacterial taxa associated with lung cancer cases in Southeast Asians: a pilot case-control study.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- The lung-brain axis: elucidating the mechanisms of pulmonary-driven neurological disorders.Journal of neuroinflammation · 2026Review
- The role of the gut-lung axis in persistent inflammation and disease progression in chronic obstructive pulmonary disease: mechanistic evidence and therapeutic implications.Frontiers in immunology · 2026Review
- Gut microbiota dysbiosis and the gut-lung axis in COPD: mechanisms, clinical relevance, and microbiota-targeted interventions.Frontiers in cell and developmental biology · 2026Review
- Research Advances on the Impact of Gut Microbiota on COPD: Exploring New Perspectives on the Microbiota-Gut-Lung Axis.Current microbiology · 2025Review
- Serum level of TNF-a, IL-1 and IL-6 and serum biomarkers after nutritional change in patients' ventilator-associated pneumonia.Journal of medical biochemistry · 2025Article
- Oral microbiota and respiratory diseases: advances and perspectives.Clinical microbiology reviews · 2025Review
- Research advance in correlation between childhood asthma and gut microbiota.Frontiers in cellular and infection microbiology · 2025Review
- Nebulization of 2% lidocaine has no detectable impact on the healthy equine respiratory microbiota.PloS one · 2025Article
- Efficacy of Prophylactic Antibiotics in COPD: A Systematic Review.Antibiotics (Basel, Switzerland) · 2024Review
- Gut virome alterations in patients with chronic obstructive pulmonary disease.Microbiology spectrum · 2024Article
- A Systematic Review of the Pulmonary Microbiome in Patients with Acute Exacerbation COPD Requiring ICU Admission.Journal of clinical medicine · 2024Review
- Dietary Fiber-Derived Microbial Butyrate Suppresses ILC2-Dependent Airway Inflammation in COPD.Mediators of inflammation · 2024Article
- The Role of the Oral Microbiome in the Development of Diseases.International journal of molecular sciences · 2023Review
- Bacterial Species and Inflammatory Cell Variability in Respiratory Tracts of Patients with Chronic Obstructive Pulmonary Disease Exacerbation: A Multicentric Study.Infection and drug resistance · 2023Article
- Longitudinal Dynamics in the Airway Bacterial Profile in Bronchiectasis.Open respiratory archivesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of interventions over the respiratory microbiome in COPD is to preserve the original microbial flora, focusing in taxa with a demonstrated impact on the prognosis of the disease. Inhaled therapy is the main treatment for COPD, and chronic corticosteroid use is recommended for patients with frequent exacerbations. This therapy, however, increases both the bronchial microbial load and the abundance of potentially pathogenic bacteria in patients with low peripheral eosinophil counts, and to minimize its use in patients without peripheral eosinophilia, when possible, may avoid increases in bacterial loads of microorganisms as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.